accountAPP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Gemcitabine...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to APP Pharmaceuticals Announces Approval And Launch Of Gemcitabine HCI For Injection, USP In 2 Gram Dosage Form
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account